Biotech Values

[BuyOnDips]

DewDiligence Share Tuesday, July 17, 2012 7:20:21 PM
Re: DewDiligence post# 145536 Post # of 145683

Clinical / Regulatory / Litigation Calendar

[Please keep these entries up to date! See
the updating procedure at the end of this post.
Items that are out of date will be removed.]

NOTE: ANYONE MAY UPDATE THIS FILE


Edits: NAVB (Lymphoseek) (AZD4694)


ABT – Bioresorbable DES: EU launch 2H12 (following reimbursement negotiations—product already approved); US launch possible in 2013 (pending clinical results).

ACHN – See http://investorshub.advfn.com/boards/read_msg.aspx?message_id=75415030 .

AGN – Latisse for androgenetic alopecia: phase-2 data in men and women late 2012.

AMGN – Xgeva sBLA submission for bone health in non-metastatic cancer: 2012-2013 pending results of phase-3 trial in breast cancer.

AMRN – AMR101 PDUFA date 7/26/12.

BMY – Eliquis in AF: CRL issued 6/25/12; no new trials needed.
BMY – Eliquis in VTE prevention: approved in EU (3/18/11); no update on timing of possible FDA submission (http://investorshub.advfn.com/boards/read_msg.aspx?message_id=58061618 ).
ELN – Bapineuzumab: see JNJ.

BMY – Yervoy in melanoma brain mets: OS data from phase-2 ‘042’ trial 2012 (?) (RR data reported at 2010 ASCO).
BMY – Yervoy in NSCLC/SCLC: OS data from phase-2 ‘041’ trial 2012 (?) (PFS data for NSCLC reported at 2010 ASCO). Decision has been made to advance to phase-3 in NSCLC. ).

GILD – PSI-7977: numerous data reports due in 2012 (too numerous to list here). .
GILD – 4-drug phase-2 all-oral HCV trial: SVR data early 2013.
GILD – Quad PDUFA date 8/27/12 (positive FDA panel 5/11/12).
GILD – “Standalone” Evitegravir: NDA submitted 6/27/12, awaiting decision on priority review.
GILD – “Standalone” Cobicstat NDA submitted 6/28/12; MAA submitted 5/23/12.
GILD – GS-7340 (Viread enhancement): Data from phase-1b dose-ranging and phase-1 combo w Emtriva: 2Q11. (Phase-2 started 1/24/12.)

IDIX – IDX184: start of unspecified all-oral combination studies promised in PR of 6/20/12.
IDIX – IDX719 (NS5A inhibitor): 3-day PoC phase-1b monotherapy data reported 6/20/12; NVS now has exclusive option to license IDX719 with a decision expected in about 3 months.

ITMN – Pirfenidone: No specific timeline for response to FDA’s CRL of 5/4/10 requesting a new trial.

JNJ – Xarelto NDA for VTE treatment/secondary prevention: on or about 11/2/12; (Xarelto NDA in PCI/ACS withdrawn on 7/10/12).
JNJ – Bapineuzumab: ‘301’/‘302’ (N. American) phase-3 trials conducted by JNJ: data 10/8/12 at American Neurological Assocation; (ex-US) phase-3 trials conducted by PFE: data in 2014.

LGND - Promacta NDA/MAA for HCV reviews pending (submissions made 5/30/12).
LGND - SCH527123 (MRK) CXCR2 antagonist p2 COPD is enrolled, data early 2012

MNTA – See http://investorshub.advfn.com/boards/read_msg.aspx?message_id=76906028
NAVB - Lymphoseek (AZD4694) http://navidea.com/about-us/message-from-ceo.html PDUFA date Sept. 10, 2012
PFE – Tofacitinib PDUFA date Aug 2012 (positive FDA panel 5/9/12).
PFE – Xalkori (crizotinib) in NSCLC: EU decision mid 2012 (MAA accepted for review 8/17/11). Approved by FDA 8/26/11.
PFE – Bosutinib in CML: PDUFA date Oct 2012; EU decision mid 2012 (MAA accepted for review 8/17/11).
PFE – Eliquis: see BMY.
PFE – Bapineuzumab: see JNJ.

REGN – Zaltrap BLA in mCRC PDUFA date 8/4/12 (priority review).

SNTA – phase 2b ganetespib + docetaxel in NSCLC: 2Q12.

SNY – Aubagio for RRMS: PDUFA date Jun 2012; in EU, MAA accepted for review 2/23/12.

SPPI - Belinostat phase-3 data: 2012 (according to PR of 3/1/12).

TEVA – Copaxone litigation: see MNTA.
TEVA – Thrice-weekly formulation of Copaxone: timing of NDA unclear according to 6/14/12 PR announcing positive top-line results from GALA study.

VRTX – Phase-2b testing multiple (non-response-guided) protocols for Incivek + VX-222 + ribavirin in treatment-naïve genotype-1 to start 3Q12. (Data on no-IFN arms of ZENITH study reported 2/23/12.)
VRTX – Initial data on studies with ALS-2200 and ALS-2158: 2Q12.

--
Procedure for Updating Calendar

When adding or modifying entries, please follow these steps:

1. Copy the complete text from the old calendar.

2. Make your additions or modifications, inserting new items in alphabetical order.

3. Near the top of the message, list the ticker symbols of the entries you changed (e.g. “Edits: GILD MNTA”).